Navigation Links
Gene assay to help to predict lung cancer treatment resistance
Date:8/26/2009

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

Ian Cree, from Queen Alexandra Hospital, Portsmouth, UK, led a team of researchers who assessed the chemosensitivity of a series of 49 NSCLC tumors and compared this with quantitative expression of putative resistance genes measured by RT-PCR. He said, "There was considerable heterogeneity between tumors, and while this showed no direct correlation with individual gene expression, there was strong correlation of multi-gene signatures for many of the single chemotherapy agents and combinations tested. This may allow the definition of predictive signatures to guide individualized chemotherapy in lung cancer".

The researchers tested docetaxel, cisplatin, gemcitabine and combinations of the agents on tumour cells taken from 49 fresh NSCLC samples. There were considerable differences between tumors in their sensitivity to individual agents and combinations, though the combination of cisplatin + gemcitabine was usually the most active.

When these results were compared to the gene expression in the tumors, Cree and his colleagues were able to identify a number of patterns, especially in chemosensitivity to combinations of treatments. Cree said, "The genes identified in this study fall into several categories, linked with much studied mechanisms such as metabolism within the cell, membrane drug pumps, and DNA repair, but also with apoptosis, suggesting that the general susceptibility of the cell to undergo this process may be an important determinant of tumor chemosensitivity, outweighing more specific mechanisms".


'/>"/>

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-319-22165
BioMed Central
Source:Eurekalert

Page: 1

Related medicine news :

1. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
2. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
3. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
4. Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays
5. Multiple Independent Studies Report on Use of Cylexs Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients
6. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
7. Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer
8. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
9. Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform
10. Battelle to Perform Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process
11. Development of Novel Assays Vital for the European Immunoassay Diagnostics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... ... 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection ... Campagna Academy in a charity drive to provide for at-risk children and teens in ... Academy is a nonprofit organization that has offered critical programs to at-risk and foster ...
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body of ... its product now available through Jet.com. , After 25 years of development, the ... is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... faith they shared to overcome struggles in life. “Our Mountains to Climb: A Journey ... Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences drive ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , August 17, 2017 DarioHealth ... Company with mobile health and big data solutions, ... agreements with domestic and non-U.S. investors for the ... and shares of the Company,s newly designated Series ... offerings. The Company expects to conduct a closing ...
(Date:8/15/2017)... HOUSTON , Aug. 15, 2017   Mostyn Law ... in Houston, Texas . The Mostyn Law ... the past 2 years. That is why Mostyn Law ... Texas to show its appreciation. Blood supplies ... to fall 5% short of hospital needs in August. That is ...
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
Breaking Medicine Technology: